Alleviation of post-radical prostatectomy cavernosal fibrosis: future directions and potential utility for PDE5 inhibitors

Author： El-Sakka Ahmed I  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.20, Iss.10, 2011-10, pp. : 1305-1309

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PDE5 inhibitors for cystic fibrosis: can they also enhance chloride transport?

By Antoniu Sabina A  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 6, 2008-06 ,pp. : 965-968

Informa Healthcare

Access to resources Recommend Favorite

Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress

By Gur Serap   Sikka Suresh C   Hellstrom Wayne JG  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 6, 2008-06 ,pp. : 855-864

Informa Healthcare

Access to resources Recommend Favorite

Prophylaxis of Erectile Function After Radical Prostatectomy with Phosphodiesterase Type 5 Inhibitors

By  

Current Pharmaceutical Design, Vol. 15, Iss. 30, 2009-10 ,pp. : 3496-3501

Bentham Science Publishers

Access to resources Recommend Favorite

PDE5 Inhibitors and their Applications

By  

Current Medicinal Chemistry, Vol. 17, Iss. 24, 2010-08 ,pp. : 2564-2587

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of PDE1 and PDE5 cGMP phosphodiesterases: patents and therapeutic potential

By Sybertz E.   Czarniecki M.  

Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 6, 1997-06 ,pp. : 631-639

Informa Healthcare

Access to resources Recommend Favorite